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GOALS
• Recognize the risk factors, signs, and symptoms of infectious endocarditis
• Understand the many approaches to diagnosing infectious endocarditis
• Appreciate the necessity of rapid treatment
• Anticipate possible complications
DEFINITION
• Infective endocarditis (IE) - a microbial infection of the heart valves (native or 
prosthetic),  the lining of a cardiac chamber or blood vessel, or a congenital 
anomaly (e.g. septal defect)
• The valves of the heart do not receive any dedicated blood supply
• As a result, defensive immune mechanisms (such as white blood cells) cannot 
directly reach the valves via the bloodstream
EPIDEMIOLOGY
• Epidemiology Incidence difficult to ascertain and varies according to location
• Much more common in males than in females
• May occur in persons of any age and increasingly common in elderly
• Mortality ranges from 20-30 %
• In developed countries， the incidence of endocarditis ranges from 4 to 7 
cases per 100，000 population per year and has remained relatively stable 
during recent decades 
• The incidence of IE involving cardiovascular implanted devices, primarily
permanent pacemakers and implanted cardioverter-defibrillators ranges
from 0.5 to 1.14 cases per 1000 device recipients and is higher among patients
with an implantable cardioverter-defibrillator than among those with a
permanent pacemaker
IMPORTANT RISK FACTORS
Some of the most important risk factors include: 
✓ Presence of a prosthetic valve (highest risk) 
✓ Previous endocarditis (highest risk) 
✓ Complex cyanotic congenital heart disease (e.g., single ventricle states) 
✓ Surgically constructed systemic pulmonary shunts or conduits
✓ Acquired valvular dysfunction (e.g., rheumatic heart disease) 
✓ Hypertrophic cardiomyopathy 
✓ Mitral valve prolapse with regurgitation
✓ IV drug abuse Important Risk Factors
OUR PATIENT
• Patient K.O.N.
• 24 y. old
• unemployed
• city resident
• Date of admission: 05 – September – 2015
COMPLAINTS
• dyspnea
• impossibility of deep inhale
• increasing of body temperature till 38◦C
• palpitation
• edemas of low extremities
• icteric skin color
ANAMNESIS MORBI
- 10 days before admission patient felt bad, appeared high body
temperature till 39◦C, yellowish color of skin, palpitation
- previously was drug addict (IV drugs injections)
- was delivered by ambulance in therapy department after
infectious diseases specialist consultation: Community –
acquired 2-sided pneumonia. Chronic toxic hepatitis.
Secondary enteropathy. Sepsis?
ANAMNESIS VITAE
• Childhood infections, injuries, tuberculosis, 
sexually transmitted diseases were denied
• Appendectomy - 2013
• Hereditary diseases are not identified
• Allergic history is not burdened
• Smoker during 5 years, do not abuse alcohol
OBJECTIVE STATUS
- Conciseness - clear, state - severe, body position - lying on his back
- Patient can orientate himself in place, time, his personality
- Yellowish skin and mucosae, herpes labialis
- Thyroid: no pathological changes
- Skeleto – muscular system - no pathological changes
- BR – 24-26 /min, Sp O2 – 91-92%
- Lung percussion: dullness below scapula angles from both sides
- Lung auscultation: weak breathing, whizzing in upper parts, crepitation – lower parts 2-sided
- Borders of the heart: right border – outside of midsternal right line on 2 cm
- Heart auscultation: rhythmic, heart tones – muffled, systolic murmur in IV point
- Pulse – rhythmic, 120 bts/min
- BP 80 / 40 mm Hg
- Abdomen: normal size, symmetric, pain during palpation in right hypochondrium
- Liver: liver margin is 3 cm below right rib cage
- Spleen: normal
- Pasternatsky symptom – negative from both sides
- Edemas: calves and feet
- Varicose vein disease of lower extremities – absent
- Stool: liquid, 2-3 times, dark color
PRELIMINARY DIAGNOSIS OF 
ADMISSION WARD PHYSICIAN
Community-acquired 2-sided pneumonia. RF II stage.
Toxic chronic hepatitis.
Sepsis?
SURVEY PLAN
• BC and urine analysis
• Electrolytes
• Liver function tests
• Serology (markers of hepatitis)
• Ultrasound of heart, liver, kidneys
• ECG
• CFC-NAC, rheumatic factor
• Blood culture 
• Chest X-ray
• Sputum analysis
• RW and AIDS – tests (on patient’s agreement)
CHEST X-RAY 05/09/15   #2271
In the middle and lower parts of
left lung can be seen
transparency decreasing due to
infiltration. Right lung – in the
middle region can be seen focal
areas of infiltration. Diaphragm's
cupulas are flattened. Sinuses are
poorly differentiated.
Flat waist of heart. Right heart
border is increased. Elongation
of aorta.
Conclusion: 2-sided pneumonia
Conclusion: sinus tachycardia
HR - 95
http://eurheartj.oxfordjournals.org/ December 6, 2015
HEART and KIDNEY ULTRASOUND
EF – 60% (N - 55 – 78%). 
On anterior leaflet of tricuspid valve is
present a high density vegetation on narrow
base – 14mm. On septal leaflets – 6 mm high
density vegetation on wide basement.
Conclusion: Dilatation of the right heart
chambers. Infective endocarditis with
involvement of tricuspid valve. Tricuspid
regurgitation 3rd degree. Right sided
nephroptosis. 2- sided hydrocalicosis.
from 11/ 09/ 2015:
05/09/15 22 / 09 / 2015 25 / 09 / 2015
After blood 
transfusion
Normal 
Range
Hemoglobin, g/l 110 37 53 130 – 160
Red blood cells, 1012 3.6 1.4
poikilocytosis
2.3
microcytosis,
poikilocytosis
4.0 – 5.0 
Color index of blood 0.9 0.79 0.79 0.85 – 1.15
Platelets, 109 240 256 180 - 320
White blood cells, 109 12 4 5.2 4 - 9
ESR, mm/h 15 82 65 1 -10
Bands 1 7% 4% 1.06 – 6%
Segments 4 78% 69% 47 – 72%
Eosinophils 69 1% 2% 0.5 – 5%
Monocytes 6 3% 9% 0.1 – 3%
Lymphocytes 20 11% 16% 19 – 37 %
BLOOD COUNT
Conclusion: hypochromic anaemia 3rd degree, stab shift on the left, lymphocytosis (05/09/15)
Patient’s ranges, N
Bilirubin, mmol/l 25 3 - 17
AST, U/L 63 < 37
ALT, U/L 52 < 41
Rheumatoid factor, IU/l 17.9 till 30
CFK-NAC, U/l 39 38-174
HBsAg 0.008 (negat) till 0.072
Anti- HCV 0.712 till 0.316
Glucose, mmol/l 4.5 3.9 – 6.4
Total protein, g/l 61 65-85
Urea, mmol/l 20.8 2.5 – 8.3
Ag p24 /Anti – HIV Ab negative negative
RW negative negative
BIOCHEMISTRY TEST DATA from 12/09/15 
Conclusion: hepatitis C, low activity
URINE TEST from 26/09/15 
Patient’s ranges N
ρ 1.009 1.001 – 1.040
glucose - -
protein 0.216 g/l -
leukocytes 25-30 1-2
hyaline casts 1-2 -
granular casts 1-2 -
pH 6,0 5-7
Conclusion: Leukocyturea, proteinurea
BLOOD CULTURE
• From 12/09/2015 #40 – sterile (negative)
• From 27/09/2015  #86 – sterile (negative)
Patients has culture-negative Infective endocarditis 

CONSULTATION OF CARDIAC SURGEON 
01/10/2015
Conclusion: Acute infectious endocarditis of IV drug users, culture
– negative, right - sided, primary affection of tricuspid valve
Recommendations: continue antibacterial treatment, routine
surgical intervention in V.T. Zaycev Institution of general and
urgent surgery NAMS of Ukraine
EF (ejection fraction) – 68% (N - 55 – 78%).
FS (function of shortening) – 31% (N – 28 – 44%)
Mitral valve: no changes
Aortic valve: no changes
Tricuspid valves: multiple vegetations. Reversed
blood flow 3+
Pulmonary trunk valve: no changes
Left ventricle:
Final diastolic size of LV cavity- 4,6 cm (N)
Final systolic size of LV cavity – 2,8 cm (N)
Left ventricle wall hypertrophy. Intraventricular
septum size – 1.5 cm
Final diastolic volume of LV cavity – 100 ml (N)
Final systolic volume of LV cavity – 31 ml (N)
Stroke volume – 68 ml (N)
Right ventricle: Increased cavity size
Right atrium: enlarged (diameter – 4.3 cm)
Left atrium: not enlarged
Conclusion: No akinesia zones. Multiple
vegetations on tricuspid valve. Tricuspid
regurgitation 3rd degree. Dilatation of the right
heart chambers. Hypertrophy of LV.
HEART ULTRASOUND from 01/ 10/ 2015:
in V.T. Zaycev Institution of general and urgent
surgery NAMS of Ukraine
The clinical diagnosis according to
current classifications
http://circ.ahajournals.org/content/early/2015/09/15/CIR.0000000000000296.abstractEuropean Society of Cardiology 2015 algorithm for diagnosis of infective endocarditis.
OUR PATIENTS HAS - DEFINITIVE DIAGNOSIS OF INF.ENDOCARDITIS
CLASSIFICATION BY DURATION
• a fulminant illness 
• associated with high fevers, systemic toxicity,
• is more likely due to Staphylococcus aureus 
• which has much greater virulence, or disease-
producing capacity and frequently causes 
metastatic infection
• Affects normal heart valves
Acute endocarditis is a hectically
febrile illness that rapidly damages
cardiac structures， seeds
extracardiac sites， and， if
untreated, progresses to death within
weeks.
• low virulence and 
• mild to moderate illness
• usually occurring in a setting of prior valvular heart 
disease
• If not treated, usually fatal by one year 
• often due to streptococci 
Subacute endocarditis follows an indolent 
course; causes structural cardiac damage 
only slowly， if at all;  rarely metastasizes; 
and is gradually progressive unless 
complicated by a major embolic event or 
a ruptured mycotic aneurysm.
OUR PATIENTS HAS ACUTE FORM OF INFECTIVE ENDOCARDITIS
CLASSIFICATION BY HEART- SIDE 
INVOLVEMENT
Right-sided infective 
endocarditis
(our patient)  
• Right-sided IE accounts for 5–10% of IE cases.
• Although it may occur in patients with a
pacemaker, ICD, central venous catheter or CHD,
this situation is most frequently observed in
IVDAs, especially in patients with concomitant
human immunodeficiency virus (HIV)
seropositivity or in immunosuppressed patients
• S. aureus is the predominant organism (60–90%
of cases), with methicillin-resistant strains
becoming more prevalent.
Pulmonary embolism is frequent in native right-
sided IE
Left-sided valve infective 
endocarditis
• Surgical treatment is required in approximately half
of the patients with IE because of severe
complications
• HF is the most frequent complication of IE
• Uncontrolled infection is one of the most feared
complications of IE and is the second most frequent
cause for surgery
• Embolic events are a frequent and life-threatening
complication of IE related to the migration of
cardiac vegetations. The brain and spleen are the
most frequent sites of embolism in left-sided IE
CLASSIFICATION BY CULTURE RESULTS
• By far the most common cause of a "culture-negative" endocarditis is prior
administration of antibiotics
• Sometimes micro-organisms can take a longer period of time to grow in the
culture media, such organisms are said to be fastidious because they have
demanding growth requirements
• Some examples include pathogens like Aspergillus species, Brucella species,
Coxiella burnetii , Chlamydia species, and HACEK bacteria
IE can be culture-positive or culture-negative
OUR PATIENT:  Blood culture - negative
HACEK BACTERIA
• HACEK organisms are a group of bacteria that live on the dental
gums, and can be seen with IV drug users who contaminate their needles
with saliva. Patients may also have a history of poor dental hygiene, or
pre-existing valvular disease.
• HAEMOPILLUS
• ACTINOBACILLUS
• CARDIOBACTERIUM HOMINIS
• EIKENELLA
• KINGELLA KINGAE
Epidemiological Clues That May be Helpful in 
Defining the Etiological Diagnosis of Culture-
Negative Endocarditis
Circulation. 2015;132:00-00. DOI: 10.1161/CIR.0000000000000296
CLASSIFICATION BY VALVE TYPE
• Prosthetic valve endocarditis can be
• early (< 60 days of valvular surgery),
• intermediate (60 days to 1 year) or
• late (> 1 year following valvular surgery)
• Early prosthetic valve endocarditis arising within 2 months of valve surgery is generally nosocomial，
the result of intraoperative contamination of the prosthesis or a bacteremic postoperative complication. 
This nosocomial origin is reflected in the primary microbial causes: S. aureus，CoNS， facultative 
gram-negative bacilli， diphtheroids， and fungi 
• PVE that presents 2一12 months after surgery often represents delayed-onset nosocomial infection
• Late prosthetic valve endocarditis beginning > 12 months after surgery is usually due to community 
acquired microorganisms
native-valve endocarditis or prosthetic-valve endocarditis
(as in our patient case)
OTHER CLASSIFICATION APPROACHES
• Other Classification Approaches Classified into 4 groups: 
• Native Valve IE
• Prosthetic Valve IE 
• Intravenous drug abuse (IVDA) IE – our patient
• Nosocomial IE
Functional Class                                      Patients symptoms
I No limitation of physical activity. Ordinary physical activity does not
cause undue fatigue, palpitation, dyspnea (shortness of breath).
II Slight limitation of physical activity. Comfortable at rest. Ordinary
physical activity results in fatigue, palpitation, dyspnea (shortness of
breath).
III Marked limitation of physical activity. Comfortable at rest. Less
than ordinary activity causes fatigue, palpitation, or dyspnea
IV Enable to carry on any physical activity without discomfort. Symptoms
of heart failure at rest. If any physical activity is undertaken,
discomfort increases.
Class Objective assessment
A No objective evidence of cardiovascular disease. No symptoms and no
limitation in ordinary physical activity.
B Objective evidence of minimal cardiovascular disease. Mild symptoms and
slight limitation during ordinary activity. Comfortable at rest.
C Objective evidence of moderately severe cardiovascular disease.
Marked limitation in activity due to symptoms, even during less-than-
ordinary activity. Comfortable only at rest.
D Objective evidence of severe cardiovascular disease. Severe limitations.
Experiences symptoms even while at rest.
HEART FAILURE CLASSIFICATION
http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes-of-Heart-Failure_UCM_306328_Article.jsp#
by NYHA (1964)
PNEUMONIA CLASSIFICATION
1. Community-acquired pneumonia (CAP) is that which occurs
in the absence of immune compromise or prior hospital
admission within the previous 30 days.
2. Hospital-acquired pneumonia (HAP) or nosocomial pneumonia 
can occur in anyone resident in hospital for > 48 h.
3. Ventilator-associated pneumonia (VAP) hospital - common in the 
intensive care unit > 48 h after endotracheal intubation
4. Pneumonia in the immunocompromised
5. Aspiration pneumonia – in those with swallowing impairment 
and neurological impairment
CURB - 65 SCALE OF PNEUMONIA 
SEVERITY
C: mental confusion
U: blood urea > 7 mmol/l (patient 20.8 mmol/l)
R: respiratory rate ≥ 30 breaths in min
B: systolic blood pressure < 90 mmHg or (patient BP – 80/40) 
diastolic blood pressure ≤ 60 mmHg
65: age ≥ 65 years
Mild pneumonia: score of 0–1 (mortality1.5%)
Moderate pneumonia: score of 2 (9%)
Severe pneumonia: score of 3–5 (22%)
BY Mean Cell Hemoglobin  (represents the average 
content of Hb in average RBC):  
I. Hypochromic anemia <27 picograms/cell
II. Hyperchromic anemia >31 picograms/cell
III. Normochromic anemia 27 - 31 picograms/cell
Classification of anemia according to the 
degree of severity 
1. Mild - hemoglobin - 120-90 g /l
2. Moderate - hemoglobin - 90-70 g /l
3. Severe - hemoglobin - less than 70 g / l 
CLASSIFICATION of ANEMIA
Sepsis: when SIRS is present in an individual patient and the cause is thought 
likely to be an infection (definitive or suspected source), sepsis is present.
DOES THIS PATIENT HAS SEPSIS?
• Temperature >38.3°C (101°F) or <36.0°C (96.8°F)
• Tachycardia >90 bpm
• Tachypnoea >20 breaths/minute
• PCO2 <4.3 kPa (32 mmHg)
• Hyperglycaemia (blood glucose >6.66 mmol/L [120 mg/dL]) in absence of diabetes mellitus
• Acutely altered mental status
• WBC count >12×10^9/L (12,000/microlitre) or <4×10^9/L (4000/microlitre), or normal WBC count with 
>10% immature forms.
The clinical criteria for the Systemic Inflammatory Response Syndrome (SIRS)
SIRS is defined by the presence of 2 or more criteria from a collection of clinical signs and laboratory
investigations as follows:
http://bestpractice.bmj.com/best-practice/monograph/245/diagnosis/criteria.html
COMPLETE DIAGNOSIS of our patient is:
Main:
Acute infectious endocarditis of IV drug users, culture – negative, right -
sided, primary affection of tricuspid valve, target organs (heart, lungs)
Complications:
Congestive Heart Failure with preserved left ventricular pump function
(ejection fraction = 60%), III C functional class by NYHA
Community-acquired 2-sided pneumonia, moderate. RF II stage.
Hypochromic anemia 3rd stage
Concomitant disease:
Chronic C hepatitis with minimal activity.
TREATMENT
DESIRED OUTCOME:
• Relieve the signs and symptoms of disease
• Decrease morbidity and mortality associated 
• Eradicate the causative organism with minimal drug exposure
• Provide cost-effective antimicrobial therapy
• Prevent IE in high-risk patients with appropriate prophylactic antimicrobials
GENERAL PRINCIPLES
• The most important approach to treatment of IE includes isolation of the infecting pathogen and 
determination of antimicrobial susceptibilities , followed by high-dose antibiotics
• Treatment usually is started in the hospital , but in selected patients, it may be completed in the outpatient 
setting
• Large doses of parenteral antimicrobials usually are necessary to achieve bactericidal concentrations 
within vegetations
• An extended duration of therapy is required, even for susceptible pathogens , because microorganisms are 
enclosed within valvular vegetations and fibrin deposits
• Treatment of IE should be started promptly. Three sets of blood cultures should be drawn at 30-min 
intervals before initiation of antibiotics.202 The initial choice of empirical treatment depends on
several considerations:
(1) Whether the patient has received previous antibiotic therapy
(2) Whether the infection affects a native valve or a prosthesis [and if so, when surgery was performed (early vs. late PVE)]
(3) The place of the infection (community, nosocomial, or nonnosocomial healthcare-associated IE) and knowledge of the local 
epidemiology, especially for antibiotic resistance and specific genuine culture-negative pathogens
(4) Cloxacillin/cefazolin administration is associated with lower mortality rates than other beta-lactams, including
amoxicillin/clavulanic acid or ampicillin/sulbactam,  and vancomycin for empirically treating MSSA endocarditis

STREPTOCOCCAL ENDOCARDITIS
• Most viridans streptococci are exquisitely sensitive to penicillin G with minimal inhibitory 
concentrations (MICs) less than or equal to 0.12 mcg/mL
• The MIC should be determined for all viridans streptococci and the results used to guide therapy 
• Approximately 10% to 20% are moderately susceptible (MIC 0.12 to 0.5 mcg/mL)
STAPHYLOCOCCAL ENDOCARDITIS
• S. aureus has become more prevalent as a cause of endocarditis because of increased IV drug abuse ,
frequent use of peripheral and central venous catheters , and valve-replacement surgery
• Coagulase-negative staphylococci ( CNST , usually S. epidermidis) are prominent causes of Prosthetic valve
endocarditis ( PVE ). The recommended therapy for patients with left-sided IE caused by methicillin-sensitive
S. aureus ( MSSA ) is 4 to 6 weeks of nafcillin or oxacillin , often combined with a short course of gentamicin
TREATMENT OF STAPHYLOCOCCUS
ENDOCARDITIS IN IV DRUG ABUSERS
• Treatment of Staphylococcus Endocarditis in IV Drug Abusers IE in IV drug abusers is most 
frequently (60% to 70%) caused by S. aureus, although other organisms may be more 
common in certain geographic locations
• Standard treatment for MSSA consists of 4 weeks of therapy with a 
penicillinase-resistant penicillin
• A 2-week course of nafcillin or oxacillin plus an aminoglycoside may be effective
• Short-course vancomycin, in place of nafcillin or oxacillin, appears to be ineffective
ENTEROCOCCAL ENDOCARDITIS
• Enterococci cause 5% to 18% of endocarditis cases and are 
noteworthy for the following reasons: 
• (1) no single antibiotic is bactericidal
• (2) MICs to penicillin are relatively high (1 to 25 mcg/mL)
• (3) they are intrinsically resistant to all cephalosporins and relatively resistant to
aminoglycosides (i.e.,“low-level” aminoglycoside resistance)
• (4) combinations of a cell wall–active agent, such as a penicillin or vancomycin, plus an
aminoglycoside are necessary for killing
• (5) resistance to all available drugs is increasing

RIGHT-SIDED INFECTIVE ENDOCARDITIS
TREATMENT
• Vegetation length > 20 mm and fungal aetiology were the main predictors of death
• The choice of empiric antimicrobial therapy depends on the suspected microorganism, type of drug and 
solvent used by the addict and the infection location
• In any case, S. aureus must always be covered
• Initial treatment includes penicillinase-resistant penicillins, vancomycin or daptomycin, depending on the 
local prevalence of MRSA,in combination with gentamicin
• If the patient is a pentazocine addict, an antipseudomonas agent should be added
• Because of limited bactericidal activity, poor penetration into vegetations and increased drug clearance in 
IVDAs, glycopeptides (vancomycin) should not be used in a 2-week treatment
• The standard 4–6-week regimen must be used in the following situations:
† Slow clinical or microbiological response (> 96 h) to antibiotic therapy
† Right-sided IE complicated by right HF, vegetations >20 mm, acute respiratory failure, septic metastatic foci 
outside the lungs (including empyema) or extracardiac complications, e.g. acute renal failure
† Therapy with antibiotics other than penicillinase-resistant penicillins
† IVDA with severe immunosuppression (CD4 count ,200 cells/mL) with or without AIDS or
† Associated left-sided IE
Antibacterial treatment Other drugs
• Levofloxacin 500mg IV 1 time/day from
05/09 till 15/09/15
• Amoxicillin/clavulonic acid IV 1000mg 2
times/day from 05/09 till 13/10/15
• Vancomycin 1gr IV 2 times/day from 14/09
till 30/09/15 (patient cannot continue therapy
due to financial problems)
• Gentamycin 80mg 2 times/day IM from
19/09 till 13/10/15
• “Biseptol” 480 mg 2 tabl 3 times/day from
22/09 till 13/10/15
• Levomicetin (Chloramphenicol) 1gr 4
times/day IV from 02/10 till 13/10/15
• Dexamethasone 8mg IV in 200ml of
5% dextrose solution #3 (low BP was)
• Trifas (torasemid) 20 mg IV 1
time/day then 10 mg/day orally
• Ampril (ramipril - eACE) 2.5 mg /
day
• Bisoprolol (b-blocker) 5 mg 1
time/day
• “Glutargin” (hepatoprotector) 1 tabl
3 times/day from 14/09 till 13/10/15
• Vicasol 1.0 ml IM 5 days
• Aminocapronic acid 100 ml IV #1
• Blood transfusion (erythrocytes
mass) 333ml gr IV (RH+) IV 24/09/15
List of medications prescribed for 
patient in hospital:
COMPLICATIONS
Four etiologies:
• Embolic 
• Local spread of infection
• Metastatic spread of infection
• Formation of immune complexes – glomerulonephritis and 
arthritis
EMBOLIC COMPLICATIONS
• Occur in up to 40% of patients with IE
• Predictors of embolization
• Size of vegetation 
• Left-sided vegetations 
• Fungal pathogens, S. aureus, and Strep. Bovis
• Incidence decreases significantly 
after initiation of effective antibiotics
• Stroke 
• Myocardial Infarction
• Fragments of valvular vegetation 
• Vegetation-induced stenosis of coronary ostia 
• Ischemic limbs
• Hypoxia from pulmonary emboli 
• Abdominal pain (splenic or renal infarction)
THEY INCLUDE:
LOCAL SPREAD OF INFECTION
• Heart failure
• Extensive valvular damage
• Paravalvular abscess (30-40%)
• Most common in aortic valve, IVDA, and S. aureus 
• May extend into adjacent conduction tissue causing arrhythmias 
• Higher rates of embolization and mortality
• Pericarditis Fistulous intracardiac connections
METASTATIC SPREAD OF INFECTION
• Metastatic abscess
• Kidneys, spleen, brain, soft tissues 
• Meningitis and/or encephalitis
• Vertebral osteomyelitis
• Septic arthritis
POOR PROGNOSTIC FACTORS
http://eurheartj.oxfordjournals.org/content/early/2015/08/28/eurheartj.ehv319
EVALUATION OF THERAPEUTIC 
OUTCOMES
EVALUATION OF THERAPEUTIC OUTCOMES assessment of signs and
symptoms, blood cultures, microbiologic tests (e.g., MIC, minimum bactericidal
concentration [MBC], or serum bactericidal titers), serum drug concentrations,
and other tests to evaluate organ function.
• Persistence of fever beyond 1 week may indicate ineffective antimicrobial
therapy, emboli, infections of intravascular catheters, or drug reactions
• In some patients, low-grade fever may persist even with appropriate
antimicrobial therapy
• After the initiation of therapy, blood cultures should be rechecked until they
are negative
Surgery Required for Optimal Outcome
• Moderate to severe congestive heart failure due to valve dysfunction
• Partially dehisced unstable prosthetic valve
• Persistent bacteremia despite optimal antimicrobial therapy
• Lack of effective microbicidal therapy (e.g. fungal or brucella endocarditis), S. aures, prosthetic valve endocarditis with an 
intracardiac complication
• Relapse of prosthetic valve endocarditis after optimal antimicrobial therapy
Surgery to Be Strongly Considered for Improved Outcomes
• Perivalvular extension of infection
• Poorly responsive S. aυres endocarditis involving the aortic or mitral valve
• Large (>1 0 mm in diameter) hypermobile vegetations with increased risk of embolism， particularly with prior embolic 
event o r with significant valve dysfunction
• Persistent unexplained fever (more then 1 0days) in culture-negative native valve endocarditis
• Poorly responsive or relapsed endocarditis due to highly antibiotic-resistant enterococci or Gram -negative bacilli
DOES THIS PATIENT REQUIRE CARDIAC 
SURGICAL INTERVENTION?
PREVENTION OF ENDOCARDITIS
Antimicrobial prophylaxis is used to prevent IE in patients believed to be at high risk. 
• The use of antimicrobials for this purpose requires consideration of the types of patients who are at
risk; the procedures causing bacteremia; the organisms that are likely to cause endocarditis; and the
pharmacokinetics, spectrum, cost, and ease of administration of available agents
• Antibiotic prophylaxis should only be considered for patients at highest risk for endocarditis,
undergoing at risk dental procedures. The main targets for antibiotic prophylaxis in these
patients are oral streptococci
• In the case of an established infection or if antibiotic therapy is indicated to prevent wound infection
or sepsis associated with a gastrointestinal or genitourinary tract procedure
• Case reports of IE after piercing and tattooing are increasing, particularly when piercing involves the
tongue, patients should be informed about the hazards of piercing and tattooing and these
procedures should be discouraged not only in high-risk patients, but also in those with native valve
disease
• The most frequent microorganisms underlying early (1 year after surgery) prosthetic valve infections
are coagulase-negative staphylococci (CoNS) and Staphylococcus aureus. Prophylaxis should be
started immediately before the procedure, repeated if the procedure is prolonged and terminated
48h afterwards.
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